Demographic, clinical, and treatment characteristics of study participants, with seropositivity rates and IgG anti-SARS-CoV-2 titers after 2-dose regimen SARS-CoV-2 vaccination.
| Entire Cohort | Seropositivity for Anti–SARS-CoV-2 IgG | Anti-SARS-CoV-2 IgG Titers, BAU/mL, Median (IQR) | |
|---|---|---|---|
| Patients, n (%) | 104 (100) | 88 (84.6) | 699.5 (283.4–1363.8) |
| Female sex, n (%) | 83 (79.8) | 70 (84.3) | |
| Age, yrs, median (IQR) | 61 (52–68) | 61 (51–67) | |
| BMI, kg/m2, median (IQR) | 27.3 (23.6–31.9) | 27.3 (23.4–32.0) | |
| Ethnicity | |||
| White, n (%) | 75 (72.1) | 61 (81.3) | |
| Arab, n (%) | 22 (21.2) | 20 (90.9) | |
| Othera, n (%) | 7 (6.7) | 7 (100) | |
| RA | |||
| Disease duration, yrs, median (IQR) | 8.5 (5–18) | 9 (5–18) | |
| RA seronegativity, n (%) | 35 (33.7) | 29 (82.9) | |
| RF seropositivity, n (%) | 63 (60.6) | 54 (85.7) | |
| ACPA seropositivity, n (%) | 58 (55.8) | 49 (84.5) | |
| Erosive disease on radiograph, n (%) | 58 (55.8) | 48 (82.8) | |
| SARS-CoV-2 vaccine, n (%) | |||
| mRNA | 83 (79.8) | 74 (89.2)b | 839.0 (376.8–1482.5)c |
| BNT162b2 mRNA | 74 (71.2) | 65 (87.8) | 800.0 (370.0–1440.0) |
| 2-dose interval, days, median (IQR) | 32 (27–35) | 33 (28–35) | |
| mRNA-1273 | 9 (8.7) | 9(100) | 1435.2 (841.0–2060.0) |
| 2-dose interval, days, median (IQR) | 28 (28–31) | 28 (28–31) | |
| ChAdOx1 nCoV-19 | 21 (20.2) | 14 (66.7)b | 404.0 (159.8–681.8)c |
| 2-dose interval, days, median (IQR) | 81 (79–84) | 81 (79–84) | |
| Immunosuppressive therapy, n (%) | |||
| csDMARDs | 82 (78.8) | 68 (82.9) | 638.3 (234.5–1310.0) |
| Monotherapy or combination csDMARDs | 23 (26.1) | 23 (100) | 1170.0 (665.3-1984.5)d |
| MTX | 76 (73.1) | 63 (82.9) | 624.0 (228.0–1320.0) |
| MTX monotherapy | 15 (17.0) | 15 (100) | 1170.0 (613.5–1984.5) |
| MTX weekly dose, mg, median (IQR) | 15 (10-15) | 15 (10-15) | |
| csDMARDs + PDN | 5 (4.8) | 4 (80.0) | 1680.0 (1026.3–5470.0) |
| b/tsDMARDs | 75 (72.1) | 60 (80.0) | 549.5 (212.0–1062.5) |
| Anti-TNF | 18 (17.3) | 18 (100) | 764.0 (383.0-1105.0) |
| Anti-IL-6 | 14 (13.5) | 12 (85.7) | 1085.0 (675.0-1560.0) |
| Abatacept | 24 (23.1) | 16 (66.7) | 476.0 (144.4–788.0) |
| RTX < 12 months before vaccine | 10 (9.6) | 6 (60.0) | 231.9 (77.8–394.8) |
| RTX < 6 months before vaccine | 6 (5.7) | 2 (33.3) | 221.3 (146.9–295.6) |
| JAKi | 9 (8.7) | 8 (88.9) | 237.5 (148.8–366) |
| b/tsDMARDs monotherapy | 17 (16.3) | 15 (88.2) | 1030.0 (623.5–1437.6) |
| b/tsDMARDs + PDN | 4 (3.8) | 4 (100) | 575.5 (324.0–1213.3) |
| csDMARDs + b/tsDMARDs | 54 (51.9) | 41 (75.9) | 403.0 (150.0–828.0) |
| csDMARDs + b/tsDMARDs without PDN | 36 (34.6) | 31 (86.1)e | 525.0 (157.0–845.0)d |
| csDMARDs + b/tsDMARDs + PDN | 18 (17.3) | 10 (55.6)e | 332.6 (125.7–434.8)d |
| PDN | 28 (26.9) | 19 (67.9) | 410.0 (225.5–1265.0) |
| PDN daily dose, mg, median (IQR) | 5 (5.0–5.0) | 5 (2.5–5.0) |
↵aBlack, Asian, or Hispanic.
↵bSARS-CoV-2 seropositivity rate of vaccination with 2-dose regimen mRNA vaccine was significantly higher compared to that with 2-dose regimen ChAdOx1 nCoV-19 vaccine. (P < 0.01).
↵cAnti-SARS-CoV-2 IgG titers were significantly higher in patients vaccinated with 2-dose regimen mRNA vaccine compared to patients with 2-dose regimen ChAdOx1 nCoV-19 vaccine (P < 0.01).
↵dAnti-SARS-CoV-2 IgG titers were significantly higher in patients treated with csDMARDs monotherapy or with a combination of csDMARDs compared to patients treated with csDMARDs associated with b/tsDMARDs with or without PDN (P < 0.05).
↵eSARS-CoV-2 seropositivity rate of combination therapy of b/tsDMARDs and csDMARDs without PDN was significantly higher compared to that of b/tsDMARDs and csDMARDs with PDN (P < 0.05). ACPA: anticitrullinated protein antibody; bDMARD: biologic DMARD; csDMARD: conventional synthetic DMARD; DMARD: disease-modifying antirheumatic drug; IL: interleukin; JAKi: Janus kinase inhibitor; MTX: methotrexate; PDN: prednisone; RA: rheumatoid arthritis; RF: rheumatoid factor; RTX: rituximab; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; TNF: tumor necrosis factor; tsDMARD: targeted synthetic DMARD.